Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
It’s becoming a daunting task to follow the field given the rapid-fire release of study results and the many recent submissions of new direct-acting antiviral (DAA) drugs. All will be given as cocktails, with or without interferon or ribavirin, and for various durations depending on genotype (GT) and other factors. How Continue reading Snapshot: HCV Drugs in Development
In a recent ‘Viewpoint’ article, Dr. Fauci, Director of NIAID, mentioned that “industry has expanded the pipeline of new antibacterial drugs…with 14-agents currently in phase 3 clinical trials”.[1] Regarding the number of drugs in late development, his statement may be correct but many of these drugs are anything but new. Reviewing Continue reading The Antibiotic Pipeline: How “New” is New